Tim Langloss

About Us BionX is a leader in the field of prosthetic devices with the introduction of the emPOWER Ankle, still the only lower-limb prosthesis with powered propulsion for enhanced mobility. Privately held and headquartered in Bedford, Mass., BionX was originally founded in 2007 as iWalk by Dr. Hugh Herr, Director and Principal Investigator of the Biomechatronics Group of MIT’s Media Laboratory, and funded by leading investment firms including WFD Ventures, General Catalyst Partners, Sigma Partners, and Gilde Healthcare Partners. The company has also received funding and support from the U.S. Department of Veterans Affairs and the U.S. Army’s Telemedicine and Advanced Technology Research Center (TATRC). Mission To develop bionic solutions that restore normalized function and improve the quality of life for people with limb pathology, while reducing healthcare costs for the payer. Vision Through our commitment to Personal Bionics, we will transcend the concept of disability and redefine the standard of care for individuals with mobility challenges. Values We believe the prosperity of our business depends on the proper treatment of patients, providers, and employees alike. We hire people who live up to our standards, which mean they believe in: • Customer Focus - Redefine the standard of care for patients while striving to exceed customer expectations. • Adaptability & Innovation - Innovate with passion and readily adapt to challenges in pursuit of our objectives. • Excellence - Pursue excellence in everything we do. • Integrity - Act with integrity to cultivate trust amongst our patients, providers and colleagues. • Teamwork - Establish an environment where teamwork as well as personal and professional fulfillment is valued.

We are a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. Our first commercial product, XHANCE® (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing our proprietary Exhalation Delivery System™ (EDS®) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). In September 2017, the U.S. Food and Drug Administration (FDA) approved XHANCE for the treatment of nasal polyps in patients 18 years of age or older. XHANCE was made widely available through commercial channels in April 2018. In March and June 2022, we announced positive top line results from our two Phase 3b clinical trials (ReOpen1 and ReOpen2) of XHANCE for a follow-on indication for the treatment of chronic sinusitis. In February 2023, we submitted a prior approval efficacy supplement (sNDA) to support the approval of a new indication for XHANCE for the treatment of chronic rhinosinusitis. If the sNDA is approved, XHANCE has the potential to be the first drug therapy approved by the FDA for the treatment of chronic sinusitis. As of February 20, 2023, we had a total of 141 full-time employees all of whom are in the United States, and no part-time employees. Culture is a critical element in the management of our organization. Our colleagues are focused on driving our business with the Optinose values as the foundation for all our efforts. Our goal is that each colleague feels a deep connection to what they do, loves coming to work and is aligned to our One Mission – to improve lives. Our values of Authenticity, Fearless Conversations, Friendship, Openness, Perseverance and Possibility Thinking guide our actions and decisions.

We are a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of our innovative therapy, Tumor Treating Fields. Our commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and in the U.S. for the treatment of adult patients with malignant pleural mesothelioma. We have ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and gastric cancer. Headquartered in Switzerland, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City. Additionally, Novocure has offices in Germany, Jersey, Japan and Israel.

SurvivorNet is the trusted source for cancer information. We believe far too many people still struggle to find information about treatments that can save their lives. SurvivorNet is closing this gap by creating a deep, video-based educational resource for patients featuring top physicians and researchers around the country. To create patient focused educational content, the company is working with physicians at leading NCCN designated cancers centers such as The National Cancer Institute, Dana Farber, Memorial Sloan Kettering, Stanford, NYU, and M.D. Anderson.

About Us BionX is a leader in the field of prosthetic devices with the introduction of the emPOWER Ankle, still the only lower-limb prosthesis with powered propulsion for enhanced mobility. Privately held and headquartered in Bedford, Mass., BionX was originally founded in 2007 as iWalk by Dr. Hugh Herr, Director and Principal Investigator of the Biomechatronics Group of MIT’s Media Laboratory, and funded by leading investment firms including WFD Ventures, General Catalyst Partners, Sigma Partners, and Gilde Healthcare Partners. The company has also received funding and support from the U.S. Department of Veterans Affairs and the U.S. Army’s Telemedicine and Advanced Technology Research Center (TATRC). Mission To develop bionic solutions that restore normalized function and improve the quality of life for people with limb pathology, while reducing healthcare costs for the payer. Vision Through our commitment to Personal Bionics, we will transcend the concept of disability and redefine the standard of care for individuals with mobility challenges. Values We believe the prosperity of our business depends on the proper treatment of patients, providers, and employees alike. We hire people who live up to our standards, which mean they believe in: • Customer Focus - Redefine the standard of care for patients while striving to exceed customer expectations. • Adaptability & Innovation - Innovate with passion and readily adapt to challenges in pursuit of our objectives. • Excellence - Pursue excellence in everything we do. • Integrity - Act with integrity to cultivate trust amongst our patients, providers and colleagues. • Teamwork - Establish an environment where teamwork as well as personal and professional fulfillment is valued.

We are a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. Our first commercial product, XHANCE® (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing our proprietary Exhalation Delivery System™ (EDS®) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). In September 2017, the U.S. Food and Drug Administration (FDA) approved XHANCE for the treatment of nasal polyps in patients 18 years of age or older. XHANCE was made widely available through commercial channels in April 2018. In March and June 2022, we announced positive top line results from our two Phase 3b clinical trials (ReOpen1 and ReOpen2) of XHANCE for a follow-on indication for the treatment of chronic sinusitis. In February 2023, we submitted a prior approval efficacy supplement (sNDA) to support the approval of a new indication for XHANCE for the treatment of chronic rhinosinusitis. If the sNDA is approved, XHANCE has the potential to be the first drug therapy approved by the FDA for the treatment of chronic sinusitis. As of February 20, 2023, we had a total of 141 full-time employees all of whom are in the United States, and no part-time employees. Culture is a critical element in the management of our organization. Our colleagues are focused on driving our business with the Optinose values as the foundation for all our efforts. Our goal is that each colleague feels a deep connection to what they do, loves coming to work and is aligned to our One Mission – to improve lives. Our values of Authenticity, Fearless Conversations, Friendship, Openness, Perseverance and Possibility Thinking guide our actions and decisions.

We are a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of our innovative therapy, Tumor Treating Fields. Our commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and in the U.S. for the treatment of adult patients with malignant pleural mesothelioma. We have ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and gastric cancer. Headquartered in Switzerland, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City. Additionally, Novocure has offices in Germany, Jersey, Japan and Israel.